MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$85,235K
Proceeds from the
exercise of stock options
$853K
(131.17%↑ Y/Y)
Sales and maturities
of investments
$60,065K
(-26.85%↓ Y/Y)
Net cash provided by
financing activities
$86,088K
(5.15%↑ Y/Y)
Net cash used in
investing activities
$46,072K
(-9.18%↓ Y/Y)
Canceled cashflow
$13,993K
Net increase in cash
and cash...
$92,579K
(140.64%↑ Y/Y)
Canceled cashflow
$39,581K
Purchase of investments
$13,993K
(-55.42%↓ Y/Y)
Accrued expenses
$9,140K
(325.51%↑ Y/Y)
Stock-based compensation
expense
$6,665K
(19.40%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,553K
(-124.47%↓ Y/Y)
Other assets
-$47K
Net cash used in
operating activities
-$39,581K
(57.95%↑ Y/Y)
Canceled cashflow
$17,405K
Net loss
-$49,893K
(47.91%↑ Y/Y)
Accounts payable
-$6,511K
(-2425.36%↓ Y/Y)
Amortization (accretion) of
bond...
-$515K
Operating lease
liabilities
-$67K
(-570.00%↓ Y/Y)
Back
Back
Cash Flow
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)
source: myfinsight.com